Physician profile
Ming-Ming Lee
NPI 1467899799
$1,017.46
in general payments reported to CMS, 2019-2025
12 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $58.66 · 2022: $52.05 · 2023: $81.95 · 2024: $395 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.13 |
| Education | $147.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $237.17 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.14 | 2022-2025 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.41 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $117.88 | 2024 | Dupixent |
| Allergan, INC. | $97.33 | 2019 | |
| Insmed, INC. | $57.65 | 2025 | Arikayce, Brinsupri |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Verona Pharma, INC. | $49.12 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $43.31 | 2024 | Keytruda |
| Harmony Biosciences LLC | $29.00 | 2023 | Wakix |
| Grifols USA, LLC | $27.13 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $23.84 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming-Ming Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.